This study investigated if treating patients who have prostate cancer with androgen receptor inhibitors (ARIs) increased their risk of falling and breaking their bones. The study found that patients who received ARI were more likely to have a fall or fracture compared to other treatments.

This trial is looking to examine the safety and effectiveness of a new drug called CYH33 in combination with olaparib (Lynparza) for the treatment of advanced solid tumors including prostate cancer. The main outcomes that are to be measured are side effects and the response rate to the treatment. This trial is being carried out in Houston, Texas, US. 

This study investigated the presence of the gene TMPRSS2-ERG in patients with metastatic castration-resistant prostate cancer on treatment outcome with taxane-based chemotherapy. Researchers reported that TMPRSS2-ERG, as identified by blood tests, is a reliable predictors of treatment success with taxane-based chemotherapy.

The authors aimed to determine patients who would benefit from early salvage radiation therapy (SRT) after prostate surgery.

The authors concluded that early SRT is only beneficial for selected patients who experience cancer recurrence after prostate surgery. 

This study investigated the quality of life after treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) with enzalutamide (Xtandi) in combination with hormone therapy. The study found that enzalutamide + hormone therapy improved the quality of life of patients, compared to hormone therapy alone.

The authors aimed to review the different types of hormone therapy and their effect on cardiovascular morbidity and death rates in men with prostate cancer.

The authors concluded that it was difficult to determine which type of hormone therapy affected the risk for cardiovascular morbidity and that further detailed research was required.

This study compared the number of hospital admissions for treatment-related complications from prostate surgery and radiation therapy. Researchers reported higher rates of treatment-related hospitalizations following radiation therapy compared to surgery.

The authors aimed to determine a patient’s ability to reach orgasm after robot-assisted laparoscopic prostatectomy (RALP) based on demographics, cancer-related and surgical variables, and erectile aids.

The authors concluded that men could reach orgasm an average of 3 years after RALP. Poor orgasmic ability was associated with men who were older, had poor erectile function and a reduced quality of life. Erectile aids also increased the rate of good ability to achieve orgasm.

The authors aimed to determine the effectiveness of video tools in improving patient knowledge of common prostate terminology. 

This study aimed to determine whether androgen deprivation therapy (ADT) is associated with an increased risk of depression for patients with prostate cancer. It found that there was an increased risk of depression.